CHOLOVUE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOVUE is an injectable diagnostic agent manufactured by Bracco, approved in 1981 as an NDA. The mechanism of action and specific indications are not publicly detailed in available data, but the product is positioned as a diagnostic imaging or contrast agent.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals declining team investment and potential consolidation in commercial roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHOLOVUE currently has zero linked open positions, reflecting its mature lifecycle stage and approaching LOE. Career opportunities are primarily in defensive commercial roles focused on market maintenance rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on CHOLOVUE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.